【4565】そーせいG 437 【第3四半期決算発表2月14日予定】

[過去ﾛｸﾞ] 【4565】そーせいG 437 【第3四半期決算発表2月14日予定】 (812ﾚｽ)
上下前次 1-新

このｽﾚｯﾄﾞは過去ﾛｸﾞ倉庫に格納されています｡
次ｽﾚ検索歴削→次ｽﾚ栞削→次ｽﾚ過去ﾛｸﾞﾒﾆｭｰ

769: (ﾜｯﾁｮｲ b78e-4G0q) 2018/02/20(火)06:00 ID:RAsWa/Kl0(2/12) AA×

769:  (ﾜｯﾁｮｲ b78e-4G0q) [] 2018/02/20(火) 06:00:48.37 ID:RAsWa/Kl0

※AstraZeneca Full-Year and Q4: AZD4635: "Data Anticipated: 2018". Phase 1b will consist of an additional expansion phase in NSCLC at the combination MTD or maximum feasible dose. (2/2)
※あすか製薬 第3四半期決算：ノルレボ売上高：当期第3四半期9.3億円(前期第3四半期8.7億円)、対前年同四半期増減率6.5％、当期年間見込12.5億円(前期年間実績11.4億円) (2/5)
※Heptares: We are now seeking a Post-Doctoral Research Scientist to join our Chemistry Team. We are now recruiting for a Medicinal / Synthetic Chemist (Scientist). "2018/2/28 Closing". (2/5)
※米国特許(MiNA)：Methods of Inducing Insulin Production. (2/6公開)
※Pluristem Quarterly Report: "Our Expectations; Sosei CVC for the clinical development and commercialization of Pluristem’s PLX-PAD cell therapy product in Japan." (2/7)
※Pluristem: Issues Letter to Shareholders: "Pluristem is working hard to negotiate the best possible terms for a Japanese JV and will provide an update upon reaching an agreement." (2/7)
※SOSEI：AstraZeneca社とのがん免疫療法分野の共同開発プログラムが順調に進行。後期第I相試験が開始。2019年後半に完了する予定。2018年第1四半期に新規併用療法臨床試験を開始予定。(2/8)
※Heptares: We are now recruiting for a "Cryo-Electron Microscopy Scientist" to join our biophysics group GPCR. "2018/3/13 Closing" (2/12up)
※ペプチドリーム決算：Heptares戦略的提携、この共同研究では、両社のもつ業界屈指のプラットフォーム技術を集結。両社での取組みは着実に進んでおり、近く進捗状況の報告が提供できる。(2/13)
※SOSE決算：研究開発費3,456百万円(48.4％増加)97.1%は英国活動。通期予想：売上収益に関する見通しを若干修正。現金収入はブレイク・イーブンから7百万米ドル損失の範囲となる見込み。(2/14)
※Heptares: We are now seeking a skilled "Computational Chemist" to Join the computational chemist team GPCR. "2018/3/15 Closing" (2/14up)
※Imperial College London: Recruit a "Research Associate" to join the research programme in Imperial Heptares project, which focuses on the "Role of GPCRs in gastrointestinal physiology". "2018/3/14 Closing" (2/15up)
※Allergan : Management's and Analysis. Long-term Obligations: Heptares Transaction: (Maximum Milestones: $ 3,224.5m, R&D / Approval: $ 649.5m, Sales Based and Other Milestones: $ 2,575.0m). (2/16)
※MiNA Therapeutics: Seeking two highly motivated and talented "Senior Technicians" to join its research team developing novel therapeutics in the field of RNA activation. "2018/4/17 Closing" (2/16up)
・・・

http://hayabusa9.5ch.net/test/read.cgi/livemarket1/1517924072/769

上下前次 1-新書関写板覧索設栞歴

あと 43 ﾚｽあります
ｽﾚ情報赤ﾚｽ抽出画像ﾚｽ抽出歴の未読ｽﾚ AAｻﾑﾈｲﾙ

ぬこの手ぬこTOP 0.071s